The present invention relates to diagnostic screens, antibodies, methods and kits for detection/ prognosis of acute myeloid leukaemia. The diagnostic screen detects the presence (+) or absence (-) of the cell surface polypeptide markers i) CD34+;ii)CD45RA+; andiii)CD90- and/ or CD123+. Antibodies specific for one or more of said cell surface polypeptide markers may be used in the diagnostic screen of the invention. Diagnostic and prognostic methods for detecting and monitoring minimal residual disease based on said screen also form part of the invention.